IL17A and myeloid sarcoma: A significant decline in the percentage of Th1, but not in IL-17+ and GM-CSF+ CD4+ T cells, and an increase in the percentage of Tregs (CD4+CD25hiFoxp3+ T cells) was observed over time in MS patients treated with ublituximab (64), and the proportion of Tregs doubled baseline values at week 48 (66).